Skip to main content
. Author manuscript; available in PMC: 2015 Mar 9.
Published in final edited form as: J Immunother. 2015 Jan;38(1):24–36. doi: 10.1097/CJI.0000000000000059

Figure 3. Auto-NK cells exhibited robust in vivo expansion, trafficked into the marrow, and exerted enhanced killing of auto-targets when HLA/KIR interactions were blocked or when ADCC was induced.

Figure 3

Figure 3

A, C. Substantial in vivo expansion of NK cells was observed for subjects 4 and 6 who received fresh auto-NK cell products produced in 10 U/mL IL2. B, D. Circulating NK cells obtained from the PB 5 days after infusion did not induce significant in vitro killing of auto-myeloma cells although killing of K562 was high. E. The highest NK cell counts post infusion were observed in subject 7, who received NK produced in 500 U/mL IL2. F. Subject 7 myeloma cells were not available for in vitro assays until day 89; however OPM2 myeloma cells and K562 were avidly killed by BM-derived NK cells obtained 5 days after infusion. G. IHC staining further confirmed the presence of CD57+ lymphocytes in the BM of subject 7. Magnification is 400x. H. Enhanced NK cell mediated killing of auto-myeloma from subjects 4, 6, and 7 was achieved by inducing ADCC with elotuzumab (Elo) or blocking ligation of inhibitory receptors with antibodies to HLA Class I and KIR. E:T Ratio is 10:1.